

DYNΛVAX

Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

July 20, 2023 at 4:15 PM EDT

EMERYVILLE, Calif., July 20, 2023 /PRNewswire/ -- [Dynavax Technologies Corporation](#) (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023, after the U.S. financial markets close.



Dynavax will host a conference call and live audio webcast on Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at <https://investors.dynavax.com/events-presentations>. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the [caller registration link](#). It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B[®] vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018[®] adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on [LinkedIn](#) and [Twitter](#).

For Investors/Media:

Paul Cox
pcox@dynavax.com
510-665-0499

Nicole Arndt
namdt@dynavax.com
510-665-7264

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/dynavax-to-report-second-quarter-2023-financial-results-and-host-conference-call-on-august-3-2023-301882521.html>

SOURCE Dynavax Technologies